SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC surges after inking pact to sell Priority Review Voucher for $195 million

30 Apr 2026 Evaluate

Sun Pharma Advanced Research Company is currently trading at Rs. 149.70, up by 1.35 points or 0.91% from its previous closing of Rs. 148.35 on the BSE.

The scrip opened at Rs. 148.05 and has touched a high and low of Rs. 163.05 and Rs. 148.05 respectively. So far 335073 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 204.25 on 02-Jun-2025 and a 52 week low of Rs. 108.20 on 23-Mar-2026.

Last one week high and low of the scrip stood at Rs. 163.05 and Rs. 114.00 respectively. The current market cap of the company is Rs. 4867.82 crore.

The promoters holding in the company stood at 65.67%, while Institutions and Non-Institutions held 2.91% and 31.42% respectively.

Sun Pharma Advanced Research Company (SPARC) has entered into a definitive asset purchase agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for $195 million upon the closing of the transaction. PRV was granted by the U.S. Food and Drug Administration (FDA) for the approval of Sezaby indicated for the treatment of neonatal seizures.

The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Stifel acted as the exclusive financial advisor to SPARC with respect to this transaction.

Sun Pharma Advanced Research Company is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery.

Sun Pharma Adv. Res Share Price

142.85 -5.50 (-3.71%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 467.90
Indegene 499.55
CMS Info Systems 290.85
JITF Infralogistics 300.00
Sagility 41.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×